Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1E | P28566 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893547 | 1.00 | TACR1 (0.47) | TACR1HTR2AMEN1KMT2ASSTR1 | |
| SCHEMBL4893559 | 1.00 | TACR1 (0.47) | TACR1HTR2AMEN1KMT2ASSTR1 | |
| SCHEMBL4886553 | 0.85 | SSTR1 (0.43) | TACR1SSTR1SSTR4HTR2CHTR2B | |
| SCHEMBL4886544 | 0.85 | SSTR1 (0.43) | TACR1SSTR1SSTR4HTR2CHTR2B | |
| SCHEMBL4925657 | 0.85 | GRM2 (0.43) | TACR1SSTR1SSTR4HTR2C | |
| SCHEMBL4925663 | 0.85 | GRM2 (0.43) | TACR1SSTR1SSTR4HTR2C | |
| SCHEMBL4925672 | 0.85 | GRM2 (0.43) | TACR1SSTR1SSTR4HTR2C | |
| SCHEMBL4886548 | 0.85 | SSTR1 (0.43) | TACR1SSTR1SSTR4HTR2CHTR2B | |
| SCHEMBL4886233 | 0.84 | SSTR1 (0.42) | TACR1SSTR1SSTR4HTR2C | |
| SCHEMBL4886238 | 0.84 | SSTR1 (0.42) | TACR1SSTR1SSTR4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | TACR1 1612/4885HTR2A 1378/4885MEN1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.